LakeShore Biopharma Co., Ltd.: 5%+ holders

As of November 9, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of LakeShore Biopharma Co., Ltd. The largest reported stake is Fung Ching Wong's, at 23.9%. 9 filings are on record since July 15, 2025 (Schedule 13D/A, July 15, 2025).

Sell to companies like LakeShore Biopharma Co., Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-06-25 · Reporting person: Huaqin Xue · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-06-25
• Filed 2026-04-29 · Holder: Crystal Peak Investment Inc. · Percent: 51% · SCHEDULE 13D/A
• Filed 2026-03-25 · Holder: Crystal Peak Investment Inc. · Percent: 51% · SCHEDULE 13D/A
• Filed 2026-02-05 · Holder: Crystal Peak Investment Inc. · Percent: 51% · SCHEDULE 13D/A
• Filed 2025-11-04 · Holder: Crystal Peak Investment Inc. · Percent: 51% · SCHEDULE 13D/A

LakeShore Biopharma Co., Ltd. has 9 Schedule 13D or 13G filings on record since 2025-07-15. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.0002 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind LakeShore Biopharma Co., Ltd. and the warning signs.

See LakeShore Biopharma Co., Ltd.'s free Snapshot Watch LakeShore Biopharma Co., Ltd.: email me the next time it files something

Free to see. No signup.

Want the whole picture on LakeShore Biopharma Co., Ltd.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on LakeShore Biopharma Co., Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on LakeShore Biopharma Co., Ltd. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies LakeShore Biopharma Co., Ltd. by CUSIP G9845F208 and gives its principal executive office as Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing, Beijing (SCHEDULE 13D/A, 2026-06-25).

Purpose of Transaction (Item 4)

Fung Ching Wong

Item 4 of the Original Schedule 13D is hereby amended to add the following information: This Amendment No. 1 is being filed to report a material decrease in the Reporting Persons' percentage of beneficial ownership of the Issuer's Ordinary Shares. This decrease resulted solely from an increase in the total number of the Issuer's issued Ordinary Shares following a private placement transaction announced by the Issuer on July 8, 2025. The Reporting Persons have not sold or otherwise disposed of any of the Ordinary Shares they beneficially own.Item 4 of the SCHEDULE 13D/A filed 2025-07-15

Crystal Peak Investment Inc.

Item 4 is hereby amended and supplemented by adding the following at the end thereof: On June 19, 2026, an extraordinary general meeting of the shareholders of the Issuer was held. At the extraordinary general meeting, the shareholders of the Issuer authorized and approved the Merger Agreement, the plan of merger (the "Plan of Merger") required to be registered with the Registrar of Companies of the Cayman Islands (the "Cayman Registrar") in connection with the Merger, and the consummation of the transactions contemplated thereby, including the Merger. Pursuant to the A&R Support Agreement entered into by and among the Rollover Shareholders, Parent and the Issuer, the Rollover Shareholders have agreed, among other things, to (i) cancel the Rollover Shares beneficially owned by them for no cash consideration and (ii) subscribe for newly issued shares of Parent at or immediately prior to the Effective Time (as defined below). The information disclosed in this paragraph does not purport to be complete and is qualified in its entirety by reference to the A&R Support Agreement, a copy of which is filed as Exhibit 99.22 to the Schedule 13D and is incorporated herein by reference in its entirety. On June 24, 2026, the Issuer and Merger Sub filed the Plan of Merger with the Cayman Registrar, which was registered by the Cayman Registrar as of June 24, 2026, pursuant to which the Merger became effective on June 24, 2026 (the "Effective Time"). As a result of the Merger, the Issuer …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-25; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns LakeShore Biopharma Co., Ltd.

Who owns LakeShore Biopharma Co., Ltd.?

On this page, one holder's latest ownership filing reports 5% or more of LakeShore Biopharma Co., Ltd.: Fung Ching Wong (23.9%, Schedule 13D/A, filed 2025-07-15).

When did Fung Ching Wong buy into LakeShore Biopharma Co., Ltd.?

The filings give report dates, not purchase dates. The earliest filing from Fung Ching Wong on this page is the Schedule 13D/A, filed 2025-07-15, reporting 23.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for LakeShore Biopharma Co., Ltd.. With no account yet, you sign up free and land on the result.

• Get an alert when LakeShore Biopharma Co., Ltd. is mentioned again
• Find former LakeShore Biopharma Co., Ltd. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes